Anti-14-3-3 Beta/Alpha antibody
Specifications
| Product Cat#: | AB-06-0080 |
| Product type: | Primary antibody |
| Antigen: | 14-3-3 Beta/Alpha |
| Immunogen: | Peptide |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:2000-4000); Immunocytochemistry (1:1:100-1:200); Immunohistochemistry-Paraffin |
| Reactivity: | Mouse, Rat and Human |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | Tris-HCl buffer (pH7.4), 0.2% BSA, 40% glycerol, 0.05% NaN3. |
| Concentration: | 1 mg/ml |
| Purity: | Immunogen affinity purified. |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | 14 3 3 alpha antibody |
| 14 3 3 protein beta/alpha antibody | |
| 14-3-3 protein beta/alpha antibody | |
| 1433B_HUMAN antibody | |
| Brain protein 14 3 3 beta isoform antibody | |
| GW128 antibody | |
| HS 1 antibody | |
| KCIP-1 antibody | |
| KCIP1 antibody | |
| N-terminally processed antibody | |
| Protein 1054 antibody | |
| Protein kinase C inhibitor protein 1 antibody | |
| YWHAA antibody | |
| YWHAB antibody |
Show More
Target information
Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis. Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2 and antagonizes its stimulatory effect on cyclin D1 expression resulting in blockage of neuronal apoptosis elicited by SRPK2. Negative regulator of signaling cascades that mediate activation of MAP kinases via AKAP13.
Provider
Erpantech Laboratory